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Background: Effectively educating families about the risks and benefits of genomic tests such as whole exome
sequencing (WES) offers numerous challenges, including the complexity of test results and potential loss of privacy.
Research on best practices for obtaining informed consent (IC) in a variety of clinical settings is needed. The BASIC3
study of clinical tumor and germline WES in an ethnically diverse cohort of newly diagnosed pediatric cancer
patients offers the opportunity to study the IC process in the setting of critical illness. We report on our experience
for the first 100 families enrolled, including study participation rates, reasons for declining enrollment, assessment of
clinical and demographic factors that might impact study enrollment, and preferences of parents for participation
in optional genomics study procedures.
Methods: A specifically trained IC team offered study enrollment to parents of eligible children for procedures
including clinical tumor and germline WES with results deposited in the medical record and disclosure of both
diagnostic and incidental results to the family. Optional study procedures were also offered, such as receiving
recessive carrier status and deposition of data into research databases. Stated reasons for declining participation
were recorded. Clinical and demographic data were collected and comparisons made between enrolled and
non-enrolled patients.
Results: Over 15 months, 100 of 121 (83%) eligible families elected to enroll in the study. No significant differences
in enrollment were detected based on factors such as race, ethnicity, use of Spanish interpreters and Spanish
consent forms, and tumor features (central nervous system versus non-central nervous system, availability of tumor
for WES). The most common reason provided for declining enrollment (10% of families) was being overwhelmed
by the new cancer diagnosis. Risks specific to clinical genomics, such as privacy concerns, were less commonly
reported (5.5%). More than 85% of parents consented to each of the optional study procedures.
Conclusions: An IC process was developed that utilizes a specialized IC team, active communication with the
oncology team, and an emphasis on scheduling flexibility. Most parents were willing to participate in a clinical
germline and tumor WES study as well as optional procedures such as genomic data sharing independent of race,
ethnicity or language spoken.* Correspondence: dwparson@bcm.edu
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The process of obtaining informed consent for subject
participation in clinical research protocols is multifa-
ceted and includes the researcher and subject or guardian
reviewing the study purpose, procedures and informed
consent document. Previous studies investigating parental
and young adult preferences for informed consent in clin-
ical trials in pediatric oncology settings have demonstrated
that participants generally prefer: (1) to receive more in-
formation but risk feeling overwhelmed with the quantity
or pace of information provided; (2) that the information
be presented in a stepwise and organized manner; and
(3) to be given sufficient time to process the informa-
tion, especially in the context of their emotional state,
before making a decision [1,2]. The presentation of add-
itional audio or visual learning materials is also sug-
gested [1]. These studies emphasize that, while there are
essential aspects of informed consent, details need to be
adapted to fit the needs and questions of the individual or
family.
The challenge of successfully informing potential par-
ticipants without overwhelming them with content can
be particularly daunting for research involving genome-
scale tests, given the amount and complexity of the in-
formation to be conveyed and the differential informa-
tional priorities and preferences of the parties involved
(patients, parents, clinicians) [3]. It is critical that the
participant understand the purpose of the research, the
type of test(s) to be performed, the various types of re-
sults that they will receive (and not receive) through
participation and in which situations they have a choice
about receipt of results in these categories, as well as
the potential risks and benefits of participation. Studies
have shown that, although the public is familiar with
the terminology of genetics and its association with dis-
ease, there are still significant gaps in conceptual know-
ledge [4-7]. Although there is limited research looking
specifically at public knowledge of concepts in the set-
ting of whole exome sequencing (WES) and whole gen-
ome sequencing (WGS), early studies have illustrated
such gaps exist but are improved by the informed con-
sent process [8]. In addition, the long-term risks of the
inclusion of genomic information in the medical record
and research databases remain unknown, although some
level of protective legislation is in place (through the
Genetic Information Nondiscrimination Act of 2008,
GINA) [9]. Thus, specific considerations for the in-
formed consent process in studies utilizing WES/
WGS include the higher likelihood of obtaining un-
anticipated results and the risk of identifiability or
loss of privacy through data sharing [10]. As is true
for other types of research, traditional barriers such as
language and education level can also factor into the
challenges of obtaining informed consent for WES/WGS studies. Previous studies have suggested a differ-
ential enthusiasm for participation in medical research
among racial and ethnic groups [11-13], but further evalu-
ation in the specific context of clinical genomic research is
needed.
Patient understanding of genomic testing in cancer pa-
tients may also be complicated by confusion over the
conceptual differences between germline mutations and
tumor or somatic mutations. Interview studies assessing
attitudes among adults diagnosed with cancer toward
personalized medicine revealed that a majority of partici-
pants expressed understanding of the difference between
germline and somatic genetic testing based on descriptions
provided to them. However, when asked about specific
benefits and risks of somatic testing some participants
described examples typically associated with germline
genetic testing, such as learning about familial risk or in-
surance discrimination, suggesting the distinction still
may have remained unclear [14].
As WES and WGS are transitioned from the labora-
tory to the clinic, there is a need for additional research
to provide insight into the best practices for obtaining
informed consent for these tests in a variety of clinical
settings. The BASIC3 (Baylor Advancing Sequencing in
Childhood Cancer Care) study seeks to integrate infor-
mation from clinical germline and tumor WES into the
care of newly diagnosed solid tumor patients at Texas
Children’s Cancer Center (TCCC) and evaluate the im-
pact of these exome data on the patients’ families and
oncologists as part of the National Human Genome Re-
search Institute Clinical Sequencing Exploratory Re-
search (CSER) program [15]. This study offers a unique
opportunity to investigate the informed consent
process for clinical germline and tumor WES in the
pediatric oncology setting. The TCCC serves a racially
and ethnically diverse patient population, including a
large number of families of Hispanic ethnicity and fre-
quently utilizing Spanish-speaking interpreters and
Spanish consent forms for both clinical care and enroll-
ment on research studies, facilitating evaluation of the
role of such factors in the informed consent process.
The goals of this manuscript are to describe the in-
formed consent process utilized for BASIC3 and to
report on our experience for the first 100 families en-
rolled, including (1) the proportion of parents who de-
cline enrollment of their child on this clinical WES
study and their reasons for doing so, (2) a comparison
of clinical and demographic factors (such as race and
ethnicity) between patients whose parents agree to or
decline study enrollment, and (3) the preferences of
parents for participation in optional genomics study
procedures such as inclusion of recessive carrier data in
WES reports and deposition of patient data into re-
search databases.
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Study design
The BASIC3 study was approved by the institutional re-
view board (IRB) of Baylor College of Medicine (BCM),
which is also the IRB for Texas Children’s Hospital
(TCH), the study clinical site. The study conformed to
the Declaration of Helsinki. Study enrollment is offered
for all patients with newly diagnosed solid tumors (in-
cluding central nervous system (CNS) tumors) under
the age of 18 years who undergo their initial tumor sur-
gery and have ongoing oncologic treatment at TCCC
and have at least one parent who speaks English or
Spanish. Enrollment for parent-specific study proce-
dures is separately offered to the parents of the patients.
All study documents, education aids and consent forms
have been fully translated into Spanish and medically
trained Spanish interpreters are utilized as needed. The
primary oncologists caring for the BASIC3 patients are
separately consented to participate in study procedures,
including oncologist interviews and surveys, but that
process is not described in detail here.
Patient-participants are enrolled in the study within
60 days of completion of the pathology report from their
diagnostic cancer surgery (Figure 1). Newly diagnosed
solid tumor patients are identified by the study team in
cooperation with the TCH surgical and neurosurgical
services, TCCC Solid Tumor and Neuro-Oncology
clinical teams, and TCH pathology. Potential eligibility
is confirmed through a review of the medical record
and in consultation with the primary oncologist.
In brief, the study procedures are as follows (Figure 1).
After informed consent for study enrollment (described in
detail below) has been obtained, patient blood and tumor
samples are sent to the Clinical Laboratory Improvement
Amendments-certified and College of American Pathologists-
certified Whole Genome and Cancer Genetics Laborator-
ies of the Medical Genetics Laboratories of BCM for
germline (including the mitochondrial DNA) and tumorFigure 1 BASIC3 clinical study design. CLIA, Clinical Laboratory Improve
counselors; MDs, pediatric oncologists; WES, whole exome sequencing.WES. If tumor sample is not available for research, pa-
tients remain eligible for the study but only germline WES
is performed. Blood samples are obtained from both bio-
logical parents when available and utilized by the labora-
tory to interpret the inheritance of germline variants
identified by WES in the patient-participant as previously
described [16]; of note, these parental samples are not
subjected to clinical WES. After the germline and tumor
WES reports are generated (turnaround time of 3 to
4 months), they are placed into the electronic health
record and reviewed with the patient’s primary oncolo-
gist by the BASIC3 principal investigators and genetic
counselor(s).
The focused germline WES reports, as previously de-
scribed [16], include all variants identified in four cat-
egories (Figure 2): (1) deleterious mutations in disease
genes related to cancer susceptibility or other patient
phenotype; (2) variants of uncertain significance in those
same phenotype-associated disease genes; (3) medically
actionable mutations in disease genes unrelated to can-
cer susceptibility; and (4) limited panel of pharmacoge-
nomic variant alleles. In addition, at the time of study
enrollment parents (or the child’s legal guardian(s), here-
after referred to as parents) are given the option to have
the report include their child’s carrier status results for
recessive disease. The germline reports utilized for this
study do not include other disease-associated mutations,
including those associated with adult-onset conditions
unrelated to cancer. The tumor WES reports (Figure 2)
comprise an annotated listing of all somatic (tumor-
specific) mutations identified in the patient’s tumor,
prioritized based upon potential clinical relevance for
the patient-participant.
After the parents have been notified that their child’s
WES results are available, an appointment is scheduled
for a ‘disclosure visit’ to review the results with their
primary oncologist and a study genetic counselor in the
TCCC clinic or inpatient oncology unit. A hard copy ofment Amendments; EHR, electronic health record; GCs, genetic
Figure 2 Categories of whole exome sequencing results returned to BASIC3 study families. PCG, pharmacogenetic; VUS, variant of
uncertain significance.
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provided to the family at this visit, which is audiore-
corded. The longitudinal aims of this study include one
parent per family being asked to complete surveys and a
subset being interviewed at three time points: after
study enrollment, after receipt of WES results, and one
year after receipt of WES results.
Informed consent process
The study team actively involved in the enrollment
process includes SEP, study PI and clinical geneticist;
DWP, study PI and pediatric oncologist; SS and KB,
study genetic counselors; RK, study coordinator. The pa-
tient’s primary pediatric oncologist advises the study
team on when an appropriate time to meet with the
family might be, given the clinical status of the patient
and the emotional state of the family. Once this ‘green
light’ has been given by the oncologist, one or more
members of the study team approaches the family about
the study. First, a brief (<10 minutes) overview of the
study is provided by the BASIC3 team and a study bro-
chure is provided. For families who express interest after
the study overview, a more detailed explanation of the
study is provided, referred to here as the consent confer-
ence. The setting for the consent conference is dictated
by the clinical status of the patient and the preferences
of the family. The information provided includes a full
description of study events (Figure 1), the types of po-
tential tumor and germline results reported (Figure 2),
and the risks and benefits of study participation. As
background for understanding the study, a brief ‘genetics
lesson’ is provided for the families, including concepts
such as how cancers develop and the distinctions be-
tween tumor (somatic) and germline mutations. Ideally,
both parents participate in this initial conference; however,often only one parent is available and the ultimate deci-
sion about study enrollment is delayed until the family
can discuss the study at home and/or a follow-up confer-
ence with the second parent is held.
Several printed visual aids (in English or Spanish) are
used to complement the informed consent document
and verbal overview. First, as noted above, a study bro-
chure is provided to parents either by the oncologist or
during the consent conference which includes a brief
introduction to the study goals and procedures, an over-
view of the relevance of germline and somatic mutations
to cancer development (with two diagrams), and a listing
of the types of potential results that may be received
during the study. Second, bulleted printed summaries of
the types of results that may be received in both the
tumor and germline reports are provided to emphasize
this important information. Finally, aids are used to
explain the concepts of carrier status for recessive
and X-linked conditions. These consist of publicly avail-
able diagrams published by the US National Library of
Medicine [17,18] as well as key facts (developed by the
study staff ) regarding each mode of inheritance, including
what it means to be a carrier, how this information applies
directly to the participant and other family members, and
reproductive risk.
Study consent forms
Separate consent forms are used for the enrollment of
patients and their parents in the study. The Patient
Consent Form (Additional file 1) on which the parent
consents to the enrollment of their child in the study
describes all key study-related events (Figure 1), includ-
ing the study samples to be obtained and the details of
the germline and tumor WES tests. The purpose of the
study is explained as learning ‘how to best report and
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hood cancer patients.’ Specific examples of the types of
potential clinically relevant tumor WES results and the
likelihood of such an event are described, such as ‘rare’
cases in which tumor findings might include mutations
that ‘are normally found in a different type of tumor
from what your child was diagnosed with’ (for example,
mutations of potential diagnostic utility) and ‘very rare’
cases in which the mutations ‘make your doctor think
your child’s tumor will respond better or worse to a par-
ticular cancer treatment’ (for example, mutations of
potential therapeutic utility). Similarly, categories and
examples of potential clinically relevant germline WES
results are provided (Figure 2), including ‘inherited mu-
tations that cause your child to have an increased risk of
developing other cancers…[and] may also provide infor-
mation about the risk of cancer in close family mem-
bers’ (for example, cancer susceptibility mutations),
‘inherited mutations that are unrelated to cancer but
provide information about a different medical condition
for which treatment is available and recommended as
standard medical care’ (for example, medically action-
able incidental findings), and ‘inherited mutations that
might affect how your child’s body responds to certain
medicines’ (for example, pharmacogenomic variants).
In addition to the required study procedures, the Pa-
tient Consent Form also includes a number of optional
elements to which parents may separately consent or de-
cline, including the option to include or exclude the
child’s recessive carrier mutations in the germline WES
report. Other choices relate to additional research proce-
dures, such as the analysis of patient samples using other
non-clinical genomic methods and the release of the
child’s genetic and clinical information into scientific da-
tabases (Table 1).Table 1 Optional BASIC3 study events listed in patient
and parent consent forms
Participant Study event
Patient Inclusion of carrier status results in germline exome report
Patient Use of diagnostic tumor sample for additional genomic
research
Patient Use of blood sample for additional genomic research
Patient Use of future tumor samples for additional genomic research
Patient Release of blood/tumor samples and genetic/clinical
information to other researchers
Patient Release of genetic and clinical information into scientific
databases
Parent Use of blood sample for additional genomic research
Parent Release of blood sample and genetic/clinical information
to other researchers
Parent Release of genetic/clinical information into scientific databases
Both Permission for future re-contactSeveral potential risks of study enrollment are in-
cluded in the consent form, including the physical risks
of obtaining a blood sample, the risk of anxiety related
to disclosure of genetic results, and the potential dis-
closure of non-paternity through genetic testing. The
risk of loss of privacy of genetic information is discussed
in relation to the collection and storage of research data
as well as the inclusion of genetic information in the
medical record, for example, ‘Health insurance compan-
ies may also have access to this information. There are
laws to protect against the use of this information in
making decisions about health insurance and employ-
ment. However, you may be asked to provide medical
record information when your child applies for life in-
surance or disability insurance’. It is stated that there
are ‘additional risks of loss of privacy’ if parents consent
to the optional study procedures of sharing genetic and
clinical data with other BCM investigators or the de-
identified release of genetic information into scientific
databases.
The possibility of identifying either tumor or germline
data that may impact the care of the patient and/or
other family members is listed as a potential benefit;
however, it is stated that ‘we do not think that the muta-
tions that are found are likely to change the planned
cancer treatment for most children’ and that in that cir-
cumstance the benefit is more to society than the individ-
ual. The probability of a tumor mutation being identified
that has implications for treatment is estimated to be
‘very rare’. It is clarified that there are no study costs for
patients and that families will be reimbursed a nominal
amount ($25) for participation in study surveys and
interviews.
For parents who decline participation for their chil-
dren we record the answer to an open-ended question:
‘Would you please tell us why you decided to not par-
ticipate’, patient tumor type, age at diagnosis, language
used during the consent conference (English or Spanish),
use of an interpreter for consent conference, and race/
ethnicity as listed in the electronic health record at the
time of initial hospital admission.
The Parent Consent Form (Additional file 1) on which
the parent consents to their own enrollment in the
study utilizes similar structure and language to the Pa-
tient Consent Form, including identical Background
and Purpose sections as well as a description of poten-
tial WES results and study risks and benefits. Informa-
tion about required and optional study samples and
procedures for the patient is replaced by a description
of optional parental blood samples that may be pro-
vided for interpretation of variants identified in the pa-
tient’s germline WES report and additional research
procedures. No parental blood samples are required
for study participation.
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As per BCM and TCCC guidelines, assent was obtained
for each child who was judged ‘capable of providing
assent based on age maturity and psychologic state’, and
documented by the parent on the Patient Consent Form
document using the standard BCM/TCCC language
(Additional file 1). TCCC standard operating procedures
for obtaining informed consent for research studies rec-
ommends that assent be obtained from subjects greater
than 6 years of age and under 18 years of age. The ex-
tent of child participation in the consent process is
guided by each child and their parents. The consent
conference(s) is conducted with the child in the room
and the child is encouraged to participate to the extent
of their interest and understanding. In only one case did
the parents specifically request to have their child not be
present for part of the discussion: a 12 year old girl with
a CNS tumor and developmental delay who was present
for most of the conference but became bothered by the
lengthy discussion of the study.
Data collection and analysis
A password-protected web accessible study database was
created to track all study events and procedures and col-
lect clinical data for enrolled subjects, including subject
age, gender, race, ethnicity, tumor diagnosis, grade, stage,
the presence of metastatic disease at diagnosis, and
whether chemotherapy and/or radiation therapy was
planned.
Subjects’ characteristics were summarized descriptively.
Comparisons were made between enrolled and non-
enrolled patients for the following variables: patient
age, gender, ethnicity, race, tumor location (CNS or
non-CNS), whether an interpreter and Spanish consent
form were used, whether tumor was available for WES,
and the time from surgery to the decision about study
enrollment. Two sample rank sum tests were used to
compare the continuous data and Fisher’s exact tests
were used for the categorical data. The P-value for eth-
nicity was calculated with ‘not reported’ subjects ex-
cluded. For race, the comparison made was between
‘white’ subjects and all others with ‘not reported’ sub-
jects excluded.
Results
The study staff began approaching all families of poten-
tially eligible newly diagnosed solid tumor patients on 1
August 2012 and the one-hundredth subject was enrolled
on 3 September 2013. Over this time period, 121 families
met eligibility criteria and were offered enrollment in the
study. Twenty-one families declined enrollment, resulting
in a rate of study enrollment of 83% (100/121, 95% confi-
dence interval 75% to 88%). Due to the complexity of the
study and the potential implications of study enrollmentfor other family members, the study consent conference is
generally conducted as a multi-step process rather than a
single meeting, with most occurring in the patient room
on the inpatient oncology floor (if the child is hospitalized)
or in the outpatient TCCC clinic, often while patients are
having chemotherapy infusions. The interval from date of
initial tumor surgery to parental decision about study en-
rollment ranged from 5 to 63 days (median 36 days) for
patients enrolled in the study. Enrolled patients were diag-
nosed with a diverse representation of pediatric solid tu-
mors. Tumor was available for WES in 84% of subjects.
Further tumor-directed treatment (chemotherapy and/or
radiation therapy) was planned for 82% of subjects. Initial
evaluation revealed that 34% of tumors were metastatic at
the time of diagnosis.
Forty-five percent of enrolled subjects were female
(Table 2). Ages ranged between 1 month and 17 years
(median of 5.1 years) at the time of tumor surgery.
Forty-three percent self-identified as being of Hispanic
ethnicity and 56% as white race. A Spanish-speaking in-
terpreter and Spanish consent form were utilized for
15% of subjects. Fourteen different oncologists had pa-
tients enrolled in the study, with the number of enrolled
patients per oncologist ranging between 1 and 22 (me-
dian 4.5, mean 7.1) and the fraction of eligible patients
per oncologist enrolling in the study ranging between
57% and 100% (Figure 3). There was no correlation be-
tween the number of patients approached per oncologist
and the fraction enrolled (Spearman’s rank correl-
ation = -0.35, P =0.21).
The most common reason provided by parents for
choosing not to participate in the study was that they
were overwhelmed by their child’s new cancer diagnosis
and did not wish to participate in an additional research
study (10% of families offered study enrollment; Figure 4).
Other reasons reported included concern about privacy
risks (3%), anxiety about receiving genetic testing results
(2.5%), and a desire for no further blood to be obtained
for research study procedures (2%).
No significant differences were detected when compar-
ing the 100 enrolled patients with the 21 patients who
were not enrolled in the study for age, gender, tumor lo-
cation (CNS or non-CNS), whether tumor was available
for WES, or the time from surgery to the decision about
study enrollment (Table 2). In addition, no significant
difference was observed in the proportion of children
identified by their parents as being of Hispanic ethnicity
between those who enrolled in the study (46% of patients
with race reported) compared with those who declined
enrollment (48%). Similarly, a Spanish interpreter and
Spanish consent forms were used in a similar proportion
of parents agreeing to (15%) or declining study enrollment
(19%). The proportion of patients identified as being of
white race was numerically but not significantly lower for
Table 2 Characteristics of patients enrolled and not enrolled in the study
Characteristic Enrolled (n = 100) Declined (n = 21) P-value
Median age in years (range) 5.1 (0.1-17.0) 4.0 (0.1-14.2) 0.73
Female gender 45 (45%) 5 (24%) 0.09
Ethnicity 1a
Hispanic 43 (43%) 10 (48%)
Non-Hispanic 51 (51%) 11 (52%)
Not reported 6 (6%) -
Race 0.17b
White 56 (56%) 18 (85%)
Black or African American 12 (12%) 1 (5%)
Asian 4 (4%) 1 (5%)
American Indian or Alaska Native 4 (4%) 1 (5%)
Multiple 6 (6%) -
Not reported 18 (18%) -
Tumor location 0.22
CNS 33 (33%) 10 (48%)
Non-CNS 67 (67%) 11 (52%)
Tumor metastatic at diagnosis 34 (34%) ND
Adjuvant tumor treatment planned 82 (82%) ND
Tumor available for WES 84 (84%) 14 (67%) 0.12
Interpreter and Spanish consent form used 15 (15%) 4 (19%) 0.74
Median days from surgery to study decision (range) 36 (5-63) 42 (20-61) 0.052
aP-value was calculated with ‘Not reported’ subjects excluded. bComparison was made between ‘White’ versus others with ‘Not reported’ subjects excluded. Two
sample rank sum tests were used to compare the continuous data and Fisher’s exact tests were used for the categorical data. CNS, central nervous system; ND,
not determined; WES, whole exome sequencing.
Figure 3 Patient enrollment by primary oncologist.
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Figure 4 Proportion of patients enrolled in the study and
stated reasons for parents declining enrollment.
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not enrolled (85%, P =0.17).
We then examined decisions about optional patient-
related study procedures made by the parents of the
enrolled children (Figure 5). Notably, 88% of parents
chose to have information about carrier status for reces-
sive diseases included in their child’s germline WES re-
port. Parents also consented to the remaining optional
study procedures at a very high rate, including use of
the diagnostic tumor sample for additional research
studies (94%), collection of tumor for research purposes
from any subsequent tumor surgeries (95%), collection
of an additional 1 to 2 teaspoon blood sample for re-
search purposes (94%), sharing of de-identified genetic
and clinical data with other BCM investigators with
IRB-approved protocols (90%), and deposition of de-
identified genetic and clinical data into scientific data-
bases (87%). All parents allowed future re-contact by
study investigators.
One hundred and forty-seven parents (1.5 parents/pa-
tient) chose to enroll in the study, resulting in 4 familiesFigure 5 Consent for optional study events. Carrier status: reporting of
diagnostic tumor for additional research studies. Subsequent tumor: use of
Additional blood: collection of blood sample for additional research studies
clinical data with other investigators for IRB-approved studies. Database de
tabases. Future re-contact: to obtain follow-up clinical information or requewith no parent enrolled, 45 with one parent enrolled,
and 51 with two parents enrolled. Two enrolled parents
were not biologically related to the enrolled child and
were not asked to provide blood samples for the study.
Most parents consented to the optional study proce-
dures (Figure 5), including collection of an additional 2
teaspoon parental blood sample for research purposes
(94%), sharing of de-identified genetic and clinical data
with other BCM investigators with IRB-approved proto-
cols (87%), and deposition of de-identified genetic and
clinical data into scientific databases (87%). All enrolled
parents allowed future re-contact by study investigators.
With regard to actual phlebotomy data, blood samples
for interpretation of their child’s germline WES results
have been obtained to date from 68% of enrolled par-
ents; blood samples for additional research have been
obtained from 67% of parents consenting to that op-
tional study procedure.
Discussion
Parents of children with newly diagnosed cancers were
found to have significant interest in a research study of
clinical and tumor WES, with more than 80% agreeing
to study enrollment. No significant differences were seen
in the clinical and demographic factors analyzed be-
tween the cohorts of patients enrolled and not enrolled
on the study, including race, ethnicity, the use of Spanish
interpreters and consent forms and the type of tumor di-
agnosed. In this clinical setting it is perhaps unsurprising
that parents would be eager to obtain any potentially
clinically relevant information that might help guide
treatment of their child’s cancer, even if it is described as
being of uncertain benefit by study investigators. This is
consistent with previous studies which demonstratedgermline carrier status for recessive diseases. Additional tumor: use of
tumor from subsequent surgeries for additional research studies.
. Data sharing: sharing of study samples and/or de-identified genetic/
posit: deposition of de-identified genetic/clinical data into scientific da-
st additional study samples.
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tients were willing to have their child undergo genetic
testing for cancer susceptibility at a time when the bene-
fits of such testing remained hypothetical [19]. However,
two observations suggest that factors other than a desire
for tumor WES results that could direct cancer therapy
also play a role in the decision of parents to enroll in the
BASIC3 study. First, most parents of patients for whom
no tumor was available for WES still consented to study
enrollment, albeit at a slightly decreased rate: 70% if no
tumor compared with 86% if tumor available (P =0.12).
This could result from the fact that our study provided
germline WES on study patients. Questions such as ‘why
did this happen to my child?’ and ‘will my other children
also get cancer?’ are a nearly universal component of ini-
tial diagnostic discussions between oncologists and fam-
ilies of newly diagnosed cancer patients. Germline WES
of their child has the potential to provide insight into
these questions by identifying pathogenic cancer suscepti-
bility mutations. Perhaps equally importantly for families,
it may help to provide reassurance that the patient’s sib-
lings are unlikely to develop a childhood cancer if no such
mutations are found. Second, a very high proportion of
parents of children enrolled in the study also agreed to op-
tional study procedures that have both immediate risks
(blood draws) and theoretical risks (privacy and insurabil-
ity concerns) despite the fact that those procedures were
not required to obtain either tumor and germline WES re-
sults, indicating that altruistic considerations were also
likely relevant to decision-making by parents regarding
enrollment in this study of clinical genomics.
Although not emphasized in discussions of genomic
sequencing, the clinical context is very important to the
consent process [20]. The period surrounding a new diag-
nosis of cancer or other life-threatening disease is one of
remarkable stress for patients and their families, which
can complicate the informed consent process [21,22]. Ac-
cordingly, we attempted to be sensitive to the specific clin-
ical and social circumstances when approaching families
about potential study enrollment, including close coordin-
ation with the primary oncologist and inpatient oncology
team for determination of the timing and ideal setting (in-
patient or outpatient) for this initial contact. For example,
several months after the study opened, we extended the
allowable window for study enrollment from 30 days to
60 days from definitive pathologic diagnosis in order to
provide additional flexibility in the consent process. Des-
pite these efforts, the reason provided by the majority of
parents who chose not to enroll their child in the study
was that they were overwhelmed by their child’s new can-
cer diagnosis and treatment and did not wish to partici-
pate in any research study. Consequently, the observed
17% rate of families declining enrollment in the study may
overestimate the proportion of parents who would declineWES in a clinical, non-study setting not requiring a long
study consent process or additional research study proce-
dures. Given that their child’s illness was the most fre-
quent explanation provided by parents for declining study
enrollment, it is possible that the children whose parents
declined were more severely ill than those who were en-
rolled in study. We did not obtain detailed clinical data on
the non-enrolled children and cannot compare the clinical
characteristics of the two groups; however, the diagnoses
of the non-enrolled patients (including five pilocytic as-
trocytomas and three Wilms tumors, both tumor types
with excellent survival rates) do not appear to carry an
unusually poor prognosis. Parental reasons for declining
enrollment related to the anticipated risks of clinical se-
quencing described in the consent form, such as the loss
of privacy and potential anxiety about genetic test re-
sults, were in aggregate reported by only 5.5% of parents
approached (for example, by 33% of parents declining
study participation).
A majority of the time during study consent confer-
ences was spent discussing the types of results that can
be discovered by tumor and germline WES (and the po-
tential clinical relevance of germline findings for other
family members) and the risks of genomic research, with
a particular emphasis on the implications of the loss of
privacy of genomic data. It was stressed to parents that
tumor and germline WES reports for patient-participants
in the study would be incorporated into the electronic
health record and that families should not participate in
the study if they objected to that required study proced-
ure. The finding that more than 80% of parents elected to
enroll their children in the study suggests that the per-
ceived risks of genomic research were outweighed for
most families by the potential benefits of study participa-
tion. This concept has been previously described among
parents offered genome scale research sequencing (where
results did not appear in the medical record) in the setting
of chronically ill children [23]. Overall, the clinical context
of the genomic study appears to play a role in the poten-
tial subjects’ willingness to participate despite potential
concerns about obtaining genetic information. In the con-
text of a child recently diagnosed with a life-threatening
condition such as cancer, parents were generally very in-
terested in participating in the study and only a small per-
centage viewed these potential ‘genetic privacy’ risks as
reason enough to decline participation. The observed rate
of enrollment in this genomic study mirrors the high par-
ticipation rates on therapeutic clinical trials for children
with cancer [24].
Our study has several key limitations which offer op-
portunities for future research. First, the data reported
do not include an assessment of parental understanding
of the study procedures or the key concepts of genetics
and genomic sequencing. The extent to which parents
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WES when they consent to their child’s participation
(and are not simply agreeing to participate in the hope
that clinically relevant information can be obtained) and
whether differences in understanding exist between the
parents who agree or decline to have their child partici-
pate in the study remain unclear. Given previous re-
search suggesting that participants in both cancer trials
[25] and genomic studies [26] often have a poor under-
standing of relevant scientific concepts and study proce-
dures, further study of this topic is needed. Data to be
obtained through longitudinal surveys and interviews of
BASIC3 study parents may provide relevant information
regarding parental understanding of study procedures
and level of satisfaction with study enrollment. Second,
relatively little information (consisting of a brief explan-
ation of reasons for declining study participation and
limited clinical and demographic data) was collected
from parents who declined participation on the study. A
more extensive analysis of study ‘decliners’ would have
the potential to provide deeper insight into the factors
behind this decision and could be useful for improving
the informed consent process, although it would be po-
tentially difficult to obtain since this group of parents
stated that they were currently overwhelmed with their
obligations. Finally, although the childhood cancer pa-
tients were present for the informed consent confer-
ences and included (to the extent of their interest and
capabilities) in study discussions, the current study does
not provide data on the details of their involvement or their
understanding of study procedures. Further research will
be required to shed light on this critical aspect of clinical
genomic studies involving pediatric patients.
Conclusions
Obtaining informed consent for clinical tumor and germ-
line WES of children with newly diagnosed cancers offers
many challenges, most fundamentally the difficulty of con-
veying complex genomic information in sufficient, but not
excessive, detail to families who are immersed in a medic-
ally and personally critical situation. We have developed
an informed consent process and document for clinical
WES in the pediatric oncology clinic that utilize a dedi-
cated informed consent team with specific genomics train-
ing and experience and rely upon active communication
with the patient’s clinical team regarding the clinical status
of the patient and the emotional status of the family. As is
the case when obtaining consent for treatment protocols
for newly diagnosed patients, flexibility in all aspects of
the informed consent process is critical at this unpredict-
able and stressful time for families [1,27], including the
timing and location of the initial conference as well as the
understanding that the ‘conference’ is in reality most often
a series of meetings involving multiple family membersand significant repetition of information, consistent
with the concept of informed consent as a process and
not a single event [28]. Although we did not collect data
on the duration of the consent conferences, we estimate
that the typical time per family is approximately an hour,
similar to that required to consent families to cancer treat-
ment protocols [29,30]. Key points in our consent forms
(Additional file 1) and the consent conference(s) include:
an explanation of the multiple different types of potential
tumor and germline WES results, with specific examples
of mutations in each category provided; an emphasis on
the fact that germline results have potential implications
for other family members; and careful explanation of the
known and unknown privacy risks of having genomic
information in the medical record, including what is
protected (and not protected) by GINA and full transla-
tion of all consent documents and educational aids for
non-English speaking families.
Most parents of children with newly diagnosed cancers
were willing to allow clinical tumor and germline WES to
be performed, as well as optional research procedures
without the possibility of direct benefit to the child or
family. In this clinical setting, we did not observe that the
willingness to participate in clinical genomics research
was significantly impacted by patient-specific factors such
as age, gender, race, or ethnicity. It is our impression that
the parents of most children with newly diagnosed cancers
are singularly focused on their child’s diagnosis and clin-
ical care and their assessment is that the potential benefit
of identifying any clinically relevant information (even if
unlikely) through WES outweighs risks of privacy loss and
genetic anxiety. Follow-up study data, including ongoing
analysis of semi-qualitative longitudinal interviews with
study parents (before and after receipt of WES results as
well as one year later), will help to shed light on this
decision-making and differences in parental perspectives
on clinical WES over time.
Additional file
Additional file 1: Patient and Parent Consent Forms for the BASIC3
study.
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